tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

NKTX Stock Latest News

Nkarta to Participate in Upcoming Investor Conference
Press ReleasesNkarta to Participate in Upcoming Investor Conference
17d ago
NKTX
Nkarta price target lowered to $20 from $25 at Mizuho
PremiumThe Fly
Nkarta price target lowered to $20 from $25 at Mizuho
1M ago
NKTX
Nkarta reports Q2 EPS (34c), consensus (45c)
PremiumThe Fly
Nkarta reports Q2 EPS (34c), consensus (45c)
1M ago
NKTX
Nkarta upgraded to Strong Buy from Outperform at Raymond James
PremiumThe Fly
Nkarta upgraded to Strong Buy from Outperform at Raymond James
1M ago
NKTX
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
PremiumPress Releases
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
1M ago
NKTX
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
PremiumPress ReleasesNkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
1M ago
NKTX
Nkarta reports Q2 EPS (34c), consensus (45c)
Premium
The Fly
Nkarta reports Q2 EPS (34c), consensus (45c)
1M ago
NKTX
Nkarta’s (NKTX) Making Promising Progress in Its Clinical-Stage Journey
Premium
Market News
Nkarta’s (NKTX) Making Promising Progress in Its Clinical-Stage Journey
1M ago
NKTX
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
PremiumPress Releases
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus
2M ago
NKTX
Nkarta initiates trial of NKX019 in lupus erythematosus
PremiumThe Fly
Nkarta initiates trial of NKX019 in lupus erythematosus
2M ago
NKTX
Nkarta Announces New President and Strategic Executive Shifts
PremiumCompany Announcements
Nkarta Announces New President and Strategic Executive Shifts
2M ago
8K
NKTX
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
PremiumPress Releases
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
2M ago
NKTX
Nkarta announces senior leadership changes
PremiumThe FlyNkarta announces senior leadership changes
2M ago
NKTX
Nkarta Advances Clinical Trials and Explores New Treatments
Premium
Company Announcements
Nkarta Advances Clinical Trials and Explores New Treatments
3M ago
8K
NKTX
Nkarta initiates trial of NKX019 in lupus nephritis
Premium
The Fly
Nkarta initiates trial of NKX019 in lupus nephritis
3M ago
NKTX
Nkarta initiates trial of NKX019 in lupus nephritis
PremiumThe Fly
Nkarta initiates trial of NKX019 in lupus nephritis
3M ago
NKTX
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
PremiumPress Releases
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
3M ago
NKTX
Nkarta’s Annual Meeting Results in Key Corporate Decisions
PremiumCompany Announcements
Nkarta’s Annual Meeting Results in Key Corporate Decisions
3M ago
8K
NKTX
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
PremiumPress Releases
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
3M ago
NKTX
Nkarta price target lowered to $15 from $16 at Canaccord
PremiumThe FlyNkarta price target lowered to $15 from $16 at Canaccord
4M ago
NKTX
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
Premium
Press Releases
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
4M ago
NKTX
Nkarta reports Q1 EPS (58c), consensus (56c)
Premium
The Fly
Nkarta reports Q1 EPS (58c), consensus (56c)
4M ago
NKTX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >